Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

Hairy cell leukemia variant (HCLv) responds poorly to purine analogue monotherapy. Rituximab concurrent with cladribine (CDAR) improves response rates, but long-term outcomes are unknown. We report final results of a phase 2 study of CDAR for patients with HCLv. Twenty patients with 0 to 1 prior cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Chihara, Dai, Arons, Evgeny, Stetler-Stevenson, Maryalice, Yuan, Constance, Wang, Hao-Wei, Zhou, Hong, Raffeld, Mark, Xi, Liqiang, Steinberg, Seth M., Feurtado, Julie, James-Echenique, Lacey, Tai, Chin-Hsien, Patel, Keyur P., Braylan, Raul C., Calvo, Katherine R., Maric, Irina, Dulau-Florea, Alina, Kreitman, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153043/
https://www.ncbi.nlm.nih.gov/pubmed/34607348
http://dx.doi.org/10.1182/bloodadvances.2021005039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153043/
https://www.ncbi.nlm.nih.gov/pubmed/34607348
http://dx.doi.org/10.1182/bloodadvances.2021005039

Ejemplares similares